HealthQuill Inc.
Merck & Co., Inc. has bought global rights for an experimental oral drug to treat heart diseases from China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. in a $2 billion deal.
Drugs Health Pharma

Merck signs $2b licensing deal with Jiangsu Hengrui for heart disease drug

HQ Team March 25, 2025: Merck & Co., Inc. has bought global rights for an experimental oral drug to treat heart diseases from.

Read More
US-based Vertex Pharmaceutical Inc. has signed a licensing pact with China’s Zai Lab Ltd. to develop and commercialise the Boston-headquartered company’s medicine, which is under trial, for treating chronic kidney diseases.
Drugs Health Pharma

Vertex, China’s Zai to develop, commercialise kidney disease drug

US-based Vertex Pharmaceutical Inc. has signed a licensing pact with China’s Zai Lab Ltd. to develop and commercialise the Boston-headquartered company’s medicine, which.

Read More